# RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2026 Q2 Balance Sheet

- Company: RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-04, accession number 0001628280-26-052533
- Page: https://plicit.ai/financials/rytm/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/rytm-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 437,266,000 US dollars
- **Current assets**: 426,563,000 US dollars
- **Non-current assets**: 10,703,000 US dollars
- **Liabilities**: 219,965,000 US dollars
- **Current liabilities**: 123,587,000 US dollars
- **Non-current liabilities**: 96,378,000 US dollars
- **Equity**: 102,983,000 US dollars
- **Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 132,500 and 132500 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $132,500 and $132,500 as of March 31, 2026, and December 31, 2025, respectively.**: 114,318,000 US dollars
- **Short-term investments**: 265,283,000 US dollars
- **Cash and cash equivalents**: 65,614,000 US dollars
- **Accounts receivable, net**: 40,408,000 US dollars
- **Inventory**: 30,517,000 US dollars
- **Prepaid expenses and other current assets**: 24,741,000 US dollars
- **Intangible assets, net**: 4,892,000 US dollars
- **Right-of-use asset**: 2,817,000 US dollars
- **Other long-term assets**: 2,288,000 US dollars
- **Restricted cash**: 603,000 US dollars
- **Property and equipment, net**: 103,000 US dollars
- **Accrued expenses and other current liabilities**: 94,016,000 US dollars
- **Accounts payable**: 16,165,000 US dollars
- **Deferred royalty obligation, current**: 12,703,000 US dollars
- **Lease liability**: 703,000 US dollars
- **Deferred revenue**: 0 US dollars
- **Deferred royalty obligation**: 93,399,000 US dollars
- **Lease liability, non-current**: 2,979,000 US dollars
- **Additional paid-in capital**: 1,560,640,000 US dollars
- **Common stock, $0.001 par value: 120,000,000 shares authorized; 68,816,868 and 67,205,321 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively**: 69,000 US dollars
- **Preferred stock, $0.001 par value: 9,850,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 1,456,814,000 US dollars
- **Accumulated other comprehensive loss**: negative 912,000 US dollars
- **Gross equity (calculated)**: 1,560,709,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus temporary equity plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.